Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population.

Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD 21205-1900, USA.
Drug and alcohol dependence (Impact Factor: 3.28). 06/2011; 119(1-2):28-36. DOI: 10.1016/j.drugalcdep.2011.05.010
Source: PubMed

ABSTRACT Little is known about the association of various psychiatric disorders with the risk of developing dependence or abuse among users of various psychoactive substances (conditional dependence, CD; conditional abuse, CA).
Evaluate the association of psychiatric disorders with CA only, CD only and CA+CD.
Secondary analysis of data from 43,093 non-institutionalized US adults in the first wave (2001-2002) of the National Epidemiological Survey on Alcohol and Related Conditions. A structured diagnostic interview allowed classification by lifetime psychiatric diagnosis (DSM-IV criteria) and psychoactive substance use. Data were analyzed using weighted proportions, 95% CIs, and weighted logistic regression models to generate odds ratios (OR) adjusted for socio-demographic characteristics.
Psychiatric disorders were associated with higher prevalence of psychoactive substance use, regardless of type of disorder or substance. CA, CD and CA+CD prevalence rates were generally higher than unconditional prevalence rates among respondents with and without psychiatric disorders. Respondents with multiple disorders (mainly mood and anxiety disorders) had higher rates of CA+CD on most, but not all, psychoactive substances (e.g., not heroin), while schizophrenia was associated only with higher rates of tranquilizer CA+CD. Psychiatric disorders had few associations with CA only and CD only on psychoactive substances.
Study findings suggest that mood and anxiety disorders are associated with increased prevalence of substance use and increased transition from use to CA and CD, while schizophrenia is associated with increased transition from abstinence to use, especially for marijuana. Findings did not support the self-medication hypothesis of substance use disorders.


Available from: Silvia Saboia Martins, Apr 18, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Despite the high prevalence of sleep disturbances in patients with co-occurring schizophrenia and substance use disorders, very little is known about sleep in this population. This paper reviews the existing literature on sleep in patients with schizophrenia and substance use disorders. Methods: PubMed and Ovid searches were performed using combinations of the terms “sleep,” “schizophrenia,” and names of commonly abused individual substances. Since searches regarding sleep in patients with dual diagnoses returned few results, we also explored the sleep abnormalities inherent in schizophrenia and in substance use disorders separately. Results: Our search identified 1,667 papers and 111 were included for review. We summarized what little is known about primary sleep disorders in this population and identified commonalities in sleep disturbances in each disease with emphasis on underlying pathophysiology as well as the effects of antipsychotics. Conclusions: Given the high prevalence of sleep abnormalities in patients with schizophrenia and substance use disorders, the relative paucity of clinical guidance, and the potential impact that sleep disorders can have on the course of disease, there is a need for additional research regarding sleep in patients with co-occurring schizophrenia and substance use disorders to improve recognition and management of these comorbid conditions.
    Journal of Dual Diagnosis 08/2013; 9(3):228-238. DOI:10.1080/15504263.2013.806088 · 0.80 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Co-occurring substance use in psychotic patients causes many subsequences including increased illness severity, decreased medication compliance, higher relapse rates, more hospitalizations, and legal problems. We aim to investigate the prevalence, patterns, associated factors and severity of substance use risk among psychotic patients in southern Thailand. Psychotic out-patients were screened with the Alcohol, Smoking, Substance Involvement Screening Test (ASSIST) for their history of substance use in the past three months and categorized as None-to-Low Risk (NLR) or Moderate-to-High Risk (MHR) levels. Multivariate logistic regression was used to examine the associated factors of substance use risk-level. The associations between substance use risk-level and emotional and behavioural symptoms, functional status and family functional status were examined using multivariate linear regression analysis. Of 663 participants screened, 322 (48.6%) used at least one substance in the past three months. Tobacco was the most common substance used (47.2%). The factors associated with a higher risk of any substance use were male gender, young age group, low level of education, being employed and being diagnosed with schizophrenia. A higher number of emotional and behavioural symptoms was significantly associated with higher substance use risk-level. In conclusion, the prevalence of substance use in psychotic patients was high and associated with their emotional and behavioural symptoms. Recommendations for implementation of screening and early intervention programs of substance-related problems in psychotic patients are important for preventing unwanted outcomes.
    Asian Journal of Psychiatry 11/2014; DOI:10.1016/j.ajp.2014.11.006
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stimulant abuse and dependence often complicate the care of people with psychotic disorders. This study systematically reviews the prevalence estimates reported for stimulant abuse and dependence in people with psychotic disorders, and examines personal, clinical, regional and methodological factors which explain variation in these rates. PsychINFO, EMBASE and MEDLINE (1946-2013) were searched systematically for studies reporting on stimulant drug use disorders in representative samples of people with psychotic disorders. Random effects models estimated the pooled rate of a stimulant use disorder, defined to include stimulant abuse and stimulant dependence. Study characteristics associated with heterogeneity in rates of stimulant use disorder were examined by subgroup analyses for categorical variables, by meta-regression for continuous independent variables and by multiple meta-regression. Sixty-four studies provided 68 estimates of lifetime or recent stimulant use disorders in 22,500 people with psychosis. The pooled rate of stimulant use disorder was 8.9% (95% CI 7.4%, 10.5%). Higher rates of stimulant use disorders were reported in studies of affective psychosis, studies from inpatient settings, studies from the USA and Australia, and studies with higher rates of cannabis disorder; in multiple meta-regression analysis these factors explained 68% of between-study variance. Rates of stimulant use disorder were stable over time, and unrelated to age, sex, stage of psychosis, type of stimulant drug or study methodology factors. Reported rates of stimulant use disorder in people with psychosis are much higher than in the general population but vary widely and are associated with regional, service setting and clinical differences between studies. It is likely that stimulants contribute to the overall burden of psychosis, and that social and environmental factors combine with drug and illness-related factors to influence stimulant use in psychosis. © The Royal Australian and New Zealand College of Psychiatrists 2014.
    Australian and New Zealand Journal of Psychiatry 12/2014; DOI:10.1177/0004867414561526 · 3.77 Impact Factor